PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer
Authors:
Open Access
- 1 January 2017
- journal article
- retracted article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (10) , 1795-1800
Abstract
Purpose: Long noncoding RNAs (lncRNAs) have been demonstrated as effective markers for cancer detection and prognosis prediction. The aim of this study was to determine whether tissue PART1 could be used as a biomarker for prognosis prediction of non-small cell lung cancer (NSCLC).Keywords
This publication has 19 references indexed in Scilit:
- Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancerBMC Research Notes, 2013
- The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancerBMC Cancer, 2013
- A long non-coding RNA signature in glioblastoma multiforme predicts survivalNeurobiology of Disease, 2013
- Long noncoding RNAs and the genetics of cancerBritish Journal of Cancer, 2013
- Long Noncoding RNAs: Past, Present, and FutureGenetics, 2013
- The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer CellsCancer Research, 2013
- The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor GrowthJournal of Thoracic Oncology, 2011
- Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival PredictionPLOS ONE, 2010
- Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder CarcinomaClinical Cancer Research, 2006
- MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancerOncogene, 2003